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Objective. To evaluate the impact of preclinical
systemic autoimmune rheumatic disorders on pregnancy
outcome.
Methods. In this longitudinal cohort study,
patients were enrolled during the first trimester of preg-
nancy if they reported having had connective tissue disor-
der symptoms, were found to be positive for circulating
autoantibodies, and on clinical evaluation were judged to
have a preclinical or incomplete rheumatic disorder. The
incidence of fetal growth restriction (FGR), preeclampsia,
and adverse pregnancy outcomes in patients with preclini-
cal rheumatic disorders was compared with that in
selected controls, after adjustment for confounders by
penalized logistic regression. Odds ratios (ORs) and 95%
confidence intervals (95% CIs) were calculated.
Results. Of 5,232 women screened, 150 (2.9%) were
initially diagnosed as having a suspected rheumatic disor-
der. After a mean6SD postpartum follow-up of 16.76 5.5
months, 64 of these women (42.7%) had no clinically
apparent rheumatic disease and 86 (57.3%) had persistent
symptoms and positive autoantibody results, including 10
(6.7%) who developed a definitive rheumatic disease. The
incidences of preeclampsia/FGR and of small for gesta-
tional age (SGA) infants were 5.1% (23 of 450) and 9.3%
(42 of 450), respectively, among controls, 12.5% (8 of 640)
(OR 2.7 [95% CI 1.1–6.4]) and 18.8% (12 of 64) (OR 2.2
[95%CI 1.1–4.5]), respectively, amongwomenwith no clin-
ically apparent disease, and 16.3% (14 of 86) (OR 3.8 [95%
CI 1.9–7.7]) and 18.6% (16 of 86) (OR 2.3 [95% CI 1.2–
4.3]), respectively, among those with persisting symptoms
at follow-up. Mean6SD umbilical artery Doppler
pulsatility indices were higher among women with no clini-
cally apparent disease (0.956 0.2) and those with
persisting symptoms (0.966 0.21) than in controls
(0.896 0.12) (P5 0.01 and P< 0.001, respectively).
Conclusion. In our study population, preclinical
rheumatic disorders were associated with an increased
risk of FGR/preeclampsia and SGA. The impact of these
findings and their utility in screening for FGR/
preeclampsia need to be confirmed in population studies.
Systemic autoimmune rheumatic diseases are
associated with increased rates of adverse pregnancy out-
comes, including spontaneous abortion, preeclampsia,
fetal growth restriction (FGR), and prematurity (1).
Systemic lupus erythematosus (SLE), rheumatoid arthri-
tis (RA), systemic sclerosis (SSc), undifferentiated con-
nective tissue disease (UCTD), and other systemic
autoimmune diseases are chronic diseases that progress
over many years and are preceded by a long period of
time with detectable autoantibodies but few symptoms
(2,3). Final diagnosis of these diseases requires the pres-
ence of several signs and symptoms according to interna-
tionally validated classification schema (4). Most affected
subjects, at least in the first stages of these diseases, have
a limited number of laboratory abnormalities and clinical
symptoms and usually do not meet classification criteria
(4,5). There is a growing body of evidence that these pre-
clinical phases can be associated with up-regulation of
inflammatory cytokines and endothelial dysfunction lead-
ing to systemic adverse effects, such as accelerated ath-
erosclerosis and cardiovascular and lung diseases (6,7).
Although retrospective epidemiologic data suggest
that adverse pregnancy outcomes often antedate the subse-
quent development of SLE, RA, SSc, or antiphospholipid
syndrome (APS), the effect of preclinical autoimmune
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systemic diseases on pregnancy outcome has not been well
studied. In a previous cohort study, using a 2-step approach
with a self-reported questionnaire and autoantibody detec-
tion, we evaluated the effects of well-defined rheumatic dis-
eases diagnosed during the first trimester on pregnancy
outcome (8). The purpose of the present study, carried out
using a similar approach, was to evaluate the effects of pre-
clinical or incomplete autoimmune systemic rheumatic
disorders detected during the first trimester of pregnancy
on pregnancy outcome.
PATIENTS AND METHODS
The study was approved by the local ethics committee.
Subjects were recruited from among unselected pregnant
women enrolled for prenatal care at our department during
the first trimester of pregnancy. As this was a pilot cohort
study conducted by only a few staff members, we restricted the
enrollment to all women seen at the clinic for prenatal care on
1 day per week only (Mondays), during a 5-year period (May
2009 to June 2014). The criteria for enrollment were as
follows: 1) singleton pregnancy, 2) prenatal care and delivery
at our department, 3) fluency in the Italian language, 4) no
previous diagnosis of or treatment for a CTD, and 5) absence
of fetal malformations or chromosomal anomalies.
The characteristics of the study and the validation of the
methods used have been reported elsewhere (8). Briefly, after
informed consent was obtained and before the medical evalua-
tion was conducted, each woman was asked to complete a screen-
ing questionnaire addressing symptoms of CTDs (Table 1).
Women who answered “yes” to 1 or more of the questions were
tested for the presence of circulating autoantibodies, including
antinuclear antibody (ANA), anti–double-stranded DNA (anti-
dsDNA), anti–extractable nuclear antigen (anti-ENA), anti-
cardiolipin antibody (aCL), anti–b2-glycoprotein I (anti–b2GPI),
and lupus anticoagulant (LAC), according to standardized meth-
ods as previously described (9). ANA was considered positive if
the titer was $1:80. Rheumatoid factor and anti–citrullinated
protein antibodies were not included in the screening autoanti-
body profile, but rather were tested only in patients with symp-
toms of arthritis found in the rheumatologic evaluation. Subjects
with a positive questionnaire response (at least 1 item) and with a
positive autoantibody test result constituted the initial population
of cases. They were referred to the rheumatology unit of our hos-
pital for further clinical assessment including careful history-
taking and physical examination. Rheumatologists were unaware
of the questionnaire results. Rheumatic diseases were classified
according to widely used criteria for UCTD (10), RA (11), SLE
(12), APS (13), Sj€ogren’s syndrome (SS) (14), SSc (15), polymyo-
sitis/dermatomyositis (16), and mixed CTD (MCTD) (17).
The final population of cases for this study consisted of
only patients with a suspected rheumatic disease (symptoms plus
autoantibodies) who did not fulfill the above-mentioned criteria
for a definite rheumatic disorder. In order to monitor for the
evolution of rheumatic disorders during pregnancy, cases were
followed up with clinical rheumatologic and laboratory evalu-
ations every 1–2 months during pregnancy and every 6–12
months after delivery, depending on the severity of symptoms.
To ensure random sampling, the first 3 subjects after
each index case who were without rheumatologic symptoms as
assessed by questionnaire and were willing to participate in the
study were tested for autoantibodies and served as the control
group. After enrollment, cases and controls were followed up
with monthly obstetric, clinical, and ultrasound evaluations. The
mean uterine artery pulsatility index in the first and second tri-
mester was evaluated according to standard methods (18).
Pulsatility indices of uterine or umbilical arteries were consid-
ered abnormal when the values were higher than the 95th per-
centile of reference curves (18). FGR was diagnosed when the
abdominal fetal circumference on ultrasonographic examination
fell below the 10th percentile of the local reference curves, con-
firmed on at least 2 consecutive measurements obtained 2
weeks apart after the standard ultrasonography performed at
18–22 weeks of pregnancy, and the pulsatility index of the
umbilical artery was higher than the 95th percentile of reference
curves, signaling reduced perfusion of the fetal placental unit.
Preeclampsia was diagnosed according to standard criteria (19).
Small for gestational age (SGA) infants were diagnosed when
birth weight was below the 10th percentile of customized Italian
growth curves (20). Moderate-to-severe pregnancy complications
included spontaneous abortion, preeclampsia, FGR, and delivery
before 34 weeks’ gestation.
Statistical analyses were carried out with one-way analysis
of variance and the Bonferroni post hoc test to compare continu-
ous variables between groups. Log-transformed data were used
when the normality assumption was not met. Categorical vari-
ables were compared by Pearson’s chi-square test. Partitioning
of chi-square statistics with Bonferroni correction for multiple
comparisons was used to evaluate the statistical significance of
pairwise comparisons in 2 3 K tables. Associations between the
diagnostic category of the rheumatic disorder and pregnancy
outcomes were evaluated using penalized logistic regression
analysis with odds ratios (ORs) and 95% confidence intervals
(95% CIs), adjusted for potential confounders (Stata 13.0 for
Windows). Penalized maximum likelihood estimation has been
proposed as a suitable method of regression analysis for uncom-
mon events (21). Logistic equations included complications of
pregnancy (preeclampsia, FGR, SGA, other moderate or severe
pregnancy complications) as outcome variables and first-
trimester smoking (yes/no), previous history of a low-birth-
weight (,2,500-gm) infant, and the diagnostic category of the
Table 1. Ten-item screening questionnaire for symptoms of a
rheumatologic disorder
1. Have you ever had generalized or localized reddening of your
skin after exposure to sunlight?
2. Have you ever had an obvious or prominent rash on your cheeks
or nose?
3. Do your hands or your feet become white in the cold and then
blue or pink?
4. a. Have you ever had painful and swollen joints?
b. Do you suffer from stiffness lasting 1 hour or more in the
morning?
5. Have you ever had pericarditis or pleuritis?
6. Do you have a dry mouth?
7. Do you feel like you have sand in your eyes?
8. Have you ever had painful white mouth ulcers?
9. Have you ever had thrombophlebitis?
10. Have you had 2 or more miscarriages or stillbirths?
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autoimmune rheumatic disease (control/no clinically apparent
disease/persisting rheumatic disorder) as explanatory variables.
Finally, to evaluate the predictors of persistence of rheumatic
disorders during follow-up among women with a suspected
rheumatic disorder at enrollment, we used stepwise logistic
regression analysis. Symptoms as depicted by questionnaire and
autoantibody testing (ANA, anti-dsDNA, aCL, and anti-b2GPI
antibodies) were inserted into the logistic model as initial
explanatory variables, and persistence of rheumatic disorders
during follow-up as the outcome measure.
RESULTS
During the study period, of 5,451 women enrolled
for prenatal care, 5,232 (96%) provided consent to partic-
ipate in the study and completed the questionnaire. The
proportion of subjects with rheumatologic symptoms
according to the questionnaire responses was 9.8% (511
of 5,232). Of the 511 subjects with symptoms, 349
(68.3%) tested positive for autoantibodies and were sent
to the rheumatology unit for evaluation and follow-up.
The 162 subjects who had symptoms but were negative
for autoantibodies were, after clinical evaluation, judged
to be negative for a preclinical rheumatic disorder and
were discharged from the study. The majority of subjects
in this subgroup (86 of 162 [53.1%]) reported only 1
symptom; in most cases this was an ocular symptom (57
of 162 [35.2%]) or photosensitivity (39 of 162 [24.1%]).
Of the 349 women with symptoms who tested pos-
itive for autoantibodies, 199 (57%) were diagnosed as
having a well-defined rheumatic disorder. Among the
entire initial group of 5,232 subjects, the prevalence of
the different rheumatic diseases diagnosed was 0.4% for
RA (19 women), 0.31% for SS (16 women), 0.27% for
primary APS (14 women), 0.25% for SLE (13 women),
and 0.08% for other miscellaneous disorders (1 subject
with SSc, 1 with MCTD, 1 with granulomatosis with poly-
angiitis [Wegener’s], and 1 with monoarticular arthritis).
UCTD was diagnosed in an additional 2.5% of the sub-
jects (131 women). Since the purpose of the study was to
evaluate the effect of preclinical or incomplete rheumatic
disorders on pregnancy outcome, these subjects with a
well-defined rheumatic disease were excluded from fur-
ther analyses. The final population of cases used in the
study was thus composed of the remaining 150 subjects
who had symptoms and were positive for autoantibodies
but did not meet criteria for definite diagnosis of a spe-
cific rheumatic disease.
The distribution of the type of antibodies detected
among cases, according to symptoms, is reported in Table 2.
Eighty-seven (58%) of the cases reported 2 symptoms and
the remaining 63 (42%) reported .2. None of the cases
tested positive for anti-ENA or LAC. One hundred nine-
teen cases (79.3%) were positive for ANA: 82 (54.7%) at a
titer of$1:80 and 37 (24.7%) at a titer of$1:160. Among
the 450 controls, 25 subjects (5.6%) tested positive for
ANA: 19 at a titer of$80 and 6 at a titer of$160. After a
mean6SD follow-up of 22.86 4.8 months from entry
into the study (median number of rheumatologic visits 7
[range 4–11]) and 16.76 5.5months postpartum, 64 of the
cases (42.7%) had no symptoms and were classified as the
no clinically apparent disease group, 10 (6.7%) were diag-
nosed as having a definite autoimmune rheumatic disease
(4 with RA, 4 with stable UCTD, and 2 with primary
APS), and 76 (50.7%) had persistent rheumatic symptoms
and positive autoantibody results but still did not meet cri-
teria for a definite rheumatic disease. Sixty-seven of the
women in the latter group were classified as having “early”
UCTD and 9 as having “non-criteria APS” (a disorder
resembling APS but not fully meeting clinical and
Table 2. Associations between rheumatologic symptoms and autoantibody results*
Symptom
Autoantibody
ANA
(n5 119)
Anti-dsDNA
(n5 2)
IgG aCL
(n5 9)
IgM aCL
(n5 22)
IgG anti-b2GPI
(n5 8)
IgM anti-b2GPI
(n5 15)
Photosensitivity (n5 85) 63 (52.9) 2 (100) 4 (44.4) 12 (54.5) 4 (50) 8 (53.3)
Erythema/malar rash (n5 81) 63 (52.9) 2 (100) 7 (77.8) 16 (72.7) 3 (37.5) 8 (53.3)
RP (n5 78) 60 (50.4) 1 (50) 5 (55.6) 13 (59.1) 5 (62.5) 10 (66.7)
Tender/swollen joints (n5 49) 41 (34.5) 2 2 3 (13.6) 3 (37.5) 4 (26.7)
Serositis (n5 5) 5 (4.2) 2 2 2 2 2
Dry mouth (n5 14) 9 (7.6) 2 1 (11.1) 3 (13.6) 2 2 (13.3)
Dry eyes (n5 22) 18 (15.1) 2 1 (11.1) 1 (4.5) 1 (6.7)
Mouth ulcers (n5 27) 22 (18.5) 2 1 (11.1) 3 (13.6) 2 (25) 1 (6.7)
Thrombophlebitis (n5 5) 4 (3.4) 2 2 1 (4.5) 2 1 (6.7)
Pregnancy loss ($2) (n5 8) 6 (5) 2 2 1 (4.5) 3 (37.5) 3 (20)
.2 symptoms (n5 63) 47 (39.5) 2 (50) 2 (22.2) 8 (36.4) 4 (50) 5 (33)
* Values are the number (%). ANA5 antinuclear antibody; anti-dsDNA5 anti2double-stranded DNA; aCL5 anticardiolipin antibody; anti-
b2GPI5 anti2b2-glycoprotein I; RP5Raynaud’s phenomenon.
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laboratory criteria for the disease). During the postpartum
follow-up, 57 (89.1%) of the 64 women classified as having
no clinically apparent disease were intermittently or per-
sistently negative for autoantibodies, and 7 (10.9%) were
persistently positive for ANA (3 at a titer of 1:80 and 4 at a
titer of 1:160).
Factors found to be independently associated with
an increased likelihood of persistence of symptoms, as a
part of either a definite or a preclinical rheumatic disor-
der, were ANA positivity at entry (76 of 86 women versus
43 of 64 women; OR 5.1 [95% CI 2–13.4]), IgG aCL posi-
tivity at entry (7 of 86 versus 2 of 64; OR 8.6 [95% CI
1.4–52.3]), and arthralgia/swollen joints (35 of 86 versus
14 of 64; OR 2.8 [95% CI 1.3–6.2]). The specificity of
these 3 parameters in the prediction of persistence of an
autoimmune disorder was 92.1% (95% CI 84.1–96.9).
During the follow-up period after the index preg-
nancy in the group of women with no clinically apparent
disease, there were 4 new pregnancies (1 complicated by
severe preeclampsia and preterm birth at 29 weeks’ gesta-
tion), with reactivation of autoimmunity and ANA results
returning to positive after having previously become nega-
tive. In the group of women with persistent rheumatic
disorders, there were 7 new pregnancies (1 complicated by
a spontaneous abortion), all characterized by the persis-
tence of rheumatic symptoms and an increase in ANA
titer compared with pre-pregnancy values.
The main demographic and clinical variables in
cases and controls are shown in Table 3. The prevalence of
smoking during the first trimester of pregnancy and that of
a history of a previous low-birth-weight infant were mar-
ginally higher among cases than among controls (P5 0.09
and P5 0.07, respectively), but none of the demographic
or variables analyzed differed significantly between cases
and controls.
The outcomes of pregnancy according to the
presence of rheumatic disease symptoms at follow-up
are reported in Table 4. Compared with controls, cases
had increased rates of defective placentation as sug-
gested by the higher Doppler pulsatility indices of uter-
ine arteries during the first and second trimesters and of
the umbilical artery during the third trimester of preg-
nancy. As a consequence, cases had increased rates of
FGR and SGA and lower infant birth weight and birth
weight centile compared with controls. Among the 86
cases with persistence of rheumatic symptoms, the
mean6SD infant birth weight and birth weight centile
were 2,8926 598 gm and 30.46 32.9, respectively (P 5
0.05 and P5 0.02 versus controls) in the 10 women with
a follow-up diagnosis of a rheumatic disease and
3,0976 523 gm and 41.46 23.8, respectively (P5 0.004
and P5 0.006 compared with negative controls) in the
76 women without a definite diagnosis. Mean6 SD
umbilical artery Doppler pulsatility indices were higher
among women with no apparent disease (0.956 0.2)
and in those with persisting symptoms (0.966 0.21)
than in controls (0.896 0.12) (P5 0.01 and P, 0.001,
respectively, compared with cases). Mean6 SD umbili-
cal artery pulsatility indices were also higher among
symptomatic women, both with and without a definite
diagnosis (1.036 0.23 and 0.956 0.21, respectively;
P5 0.004 and P5 0.001 versus controls).
Moderate or severe pregnancy complications
(spontaneous abortion, preeclampsia, FGR, delivery
before 34 weeks’ gestation) were more common among
women with rheumatic symptoms than among controls.
Table 3. Sociodemographic variables in the cases and controls*
Controls
(n5 450)
Cases
No clinically
apparent disease
(n5 64)
Persistence
of symptoms
(n5 86)
Overall
(n5 150)
Maternal age, mean6 SD years 33.496 4.22 33.396 4.03 33.546 4.77 33.476 4.45
BMI, mean6 SD kg/m2 23.076 3.44 22.756 3.17 22.746 3.12 22.746 3.13
Nulliparous 315 (70) 42 (65.6) 54 (62.8) 96 (64)
First-trimester smoking 61 (13.6) 14 (21.9) 15 (17.4) 29 (19.3)
Education
,5 years 3 (0.7) 1 (1.6) 2 (2.3) 3 (2)
628 years 73 (16.2) 8 (12.5) 11 (12.8) 19 (12.7)
9213 years 244 (54.2) 36 (56.2) 40 (46.5) 76 (50.7)
.13 years 130 (28.9) 19 (29.7) 33 (38.4) 52 (34.7)
Chronic hypertension 3 (0.7) 2 1 (1.2) 1 (0.6)
Previous low-birth-weight
infant (,2,500 gm)
3 (0.7) 3 (4.7) 1 (1.2) 4 (2.6)
* Except where indicated otherwise, values are the number (%). There were no statistically significant
differences between the overall case group and the control group. BMI5 body mass index.
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In post hoc analysis and after Bonferroni correction for
multiple comparisons, there were no significant differ-
ences in the uterine and umbilical artery pulsatility
index or in birth weight and birth weight centile among
cases with no clinically apparent disease compared with
those with persistence of rheumatic symptoms. In con-
trast, in both of these groups of cases the pulsatility
index of the uterine and umbilical artery was signifi-
cantly increased, and birth weight and birth weight
centile were significantly reduced, compared with
Table 4. Pregnancy outcomes in the cases and controls*
Cases
Controls
(n5 450)
No clinically
apparent disease
(n5 64)
Persistence of
symptoms
(n5 86)
Overall
(n5 150)
P, overall
case group
vs. controls
Gestational age at delivery,
mean6 SD weeks
39.16 1.8 39.06 1.81 38.886 2.0 38.96 1.92 0.57
Birth weight, mean6 SD gm 3,270.356 483.2 3,102.316 446.6† 3,073.876 525.6† 3,0866 492.1 0.000
Birth weight,
mean6 SD centile
51.156 28.44 40.266 26.38† 40.266 25.04† 40.266 25.55 0.000
First-trimester uterine
artery pulsatility index,
mean6 SD
1.166 0.38 1.416 0.36† 1.356 0.43† 1.376 0.42 0.000
Second-trimester uterine
artery pulsatility index,
mean6 SD
0.876 0.37 1.056 0.27† 0.976 0.30† 1.006 0.29 0.000
Third-trimester umbilical
artery pulsatility index,
mean6 SD
0.896 0.12 0.956 0.20† 0.966 0.21† 0.956 0.20 0.000
First-trimester bilateral
uterine artery notch
14 (3.1) 7 (10.9)† 7 (8.1) 14 (9.3) 0.003
Persistent bilateral
uterine artery notch
10 (2.2) 5 (7.8)† 4 (4.6) 9 (6) 0.03
Umbilical artery pulsatility
index .95th percentile
16 (3.6) 8 (12.5)† 16 (18.6)† 24 (16) ,0.001
Cesarean section 137 (30.4) 18 (28.1) 28 (32.6) 46 (30.6) 1
Fetal death 2 2 1 (1.2) 1 (0.7) 0.25
Gestational diabetes 8 (1.8) 2 (3.1) 4 (4.6) 6 (4.0) 0.13
Small for gestational age 42 (9.3) 12 (18.7) 16 (18.6)† 28 (18.7) 0.002
Fetal growth restriction 16 (3.6) 8 (12.5)† 12 (13.9)† 20 (13.3) ,0.001
Preeclampsia 12 (2.7) 3 (4.7) 6 (7.0) 9 (6) 0.07
Preeclampsia or fetal
growth restriction
23 (5.1) 8 (12.5)† 14 (16.3)† 22 (14.7) ,0.001
Delivery at ,34 weeks 9 (2.0) 2 (3.1) 2 (2.3) 4 (2.6) 0.75
Moderate or severe
adverse outcomes
22 (4.9) 6 (9.4) 12 (13.9)† 18 (12) 0.004
* Except where indicated otherwise, values are the number (%).
† P, 0.05 versus controls, by post hoc testing with Bonferroni correction for multiple comparisons.
Table 5. Odds ratios in the cases (versus the control group [referent]) for adverse pregnancy
outcomes according to rheumatic disease status*
No clinically
apparent disease
(n5 64)
Persistence of
symptoms
(n5 86)
Overall
(n5 150)
Preeclampsia 1.9 (0.526.7) 2.9 (0.925.7) 2.4 (0.925.7)
Fetal growth restriction 3.8 (1.629.5) 4.6 (2.1210.0) 4.2 (2.128.3)
Preeclampsia or fetal growth restriction 2.7 (1.126.4) 3.8 (1.927.7) 3.3 (1.826.1)
Small for gestational age 2.2 (1.124.5) 2.3 (1.224.3) 2.2 (1.323.8)
Any adverse pregnancy outcome 2.0 (0.725.1) 3.2 (1.526.7) 2.6 (1.425.0)
* Values are the odds ratio (95% confidence interval), obtained by penalized logistic regression includ-
ing pregnancy outcome as the dependent variable and rheumatic disease status (controls/no clinically
apparent disease/persistence of symptoms), previous low-birth-weight infant (yes/no), and first-trimester
smoking (yes/no) as explanatory variables.
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controls. Compared with controls and after correction
for multiple comparisons, moderate/severe com-
plications of pregnancy were significantly more common
only in the group of cases with persistence of rheumatic
symptoms.
Table 5 presents the results of penalized logistic
regression analysis. Compared with controls and after cor-
rection for potential confounders, measures of fetal growth,
such as the prevalence of SGA as obtained with customized
growth charts and FGR with abnormal Doppler findings,
were significantly higher both in the group of women with
no clinically apparent disease and in those with persisting
rheumatic symptoms. Logistic analysis confirmed that only
the subgroup of cases with persisting rheumatic symptoms
had increased rates of moderate/severe pregnancy com-
plications compared with controls.
DISCUSSION
Data from multiple previous studies suggest that
systemic autoimmune diseases, such as SLE, RA, SSc, SS,
and APS, are often preceded (for a long period of time,
often lasting several years) by the presence of detectable
autoantibodies and few signs or symptoms, not fulfilling
diagnostic criteria for a definite rheumatic disease (2,3).
The clinical phases that antedate the development of an
overt autoimmune disorder have often been referred to as
early, incomplete, undifferentiated, or preclinical autoim-
mune rheumatic disease (4,5,22,23). Earlier phases of auto-
immune diseases or incomplete disorders are not entirely
benign and have been associated with increased rates of
cardiovascular and lung disorders, accelerated atheroscle-
rosis, and, at least for non-criteria APS, increased rates of
adverse obstetric events (24,25).
Our results showed that in pregnant women with
mild preclinical or incomplete rheumatic diseases detected
during the first trimester of pregnancy, the rates of fetal
growth disorders and of adverse obstetric events were signif-
icantly higher than those in negative controls. The increased
Doppler pulsatility index of the uterine artery during the
first and second trimesters and of the umbilical artery during
the third trimester of pregnancy suggest that the increased
risk of fetal growth failure among pregnant women with
rheumatic symptoms and antibodies was a direct conse-
quence of defective placentation. Although we were able to
demonstrate increased rates of adverse pregnancy outcomes
only among subjects with persistence of rheumatologic
symptoms after delivery, women with transient rheumato-
logic symptoms and autoantibody positivity during preg-
nancy had increased rates of either preeclampsia/FGR or
SGA, relative to negative controls.
The prospective design with recruitment during the
first trimester of pregnancy and subsequent evaluation of
both rheumatologic and obstetric outcomes are the main
strengths of the present study. Previous epidemiologic
investigations into the relationship between obstetric ante-
cedents of subsequent rheumatic diseasewere basedmainly
on retrospective evaluations of obstetric history before the
development of a definite rheumatic disease (26,27). Van
Wyk et al have shown that, compared with healthy controls,
the reproductive history of womenwho later developed SSc
was characterized by increased rates of FGR and pre-
eclampsia (28). Other retrospective studies of obstetric his-
tory before and after a diagnosis of SLE (29) suggested that
preclinical SLEwas associated with increased rates of FGR
and pregnancy complications. In a recent study, Arkema
and colleagues (30), using population-based Swedish regis-
tries, found that compared with the general population,
women with pre-SLE had increased rates of preeclampsia,
premature delivery, and adverse neonatal outcomes such as
infection andmortality.
A large, epidemiologic, population-based retro-
spective study inDenmark showed that children exposed to
preclinical maternal RA were more often born preterm
and with a placental and neonatal weight lower than that
recorded among unexposed controls (31). Finally, the so-
called non-criteria APS, that is, the presence of incomplete
clinical and/or laboratory manifestations of APS, is associ-
ated with an increased risk of pregnancy complications,
such as recurrent fetal loss and adverse pregnancy out-
comes mediated by placental insufficiency (25). Our results
are consistent with all of these data suggesting that early,
preclinical, or incomplete autoimmune rheumatic diseases
diagnosed during the first trimester of pregnancy are asso-
ciated with increased rates of preeclampsia and/or fetal
growth failure.
Whereas the association of preclinical autoimmune
disorders with persisting postpartum symptoms and
adverse pregnancy outcome seems convincing, the associa-
tion of increasing rates of preeclampsia or FGR among
subjects with transient clinical and laboratory rheumatic
abnormalities during pregnancy with subsequent classifica-
tion as having no clinically apparent rheumatic disease is
less obvious. However, previously reported data suggest
that the detection of antiphospholipid antibodies is associ-
ated with increased rates of pregnancy failure and subse-
quent pregnancy complications, irrespective of the
simultaneous presence of rheumatologic symptoms (32). In
addition, ANAs have been associated with recurrent preg-
nancy loss and with increased rates of preeclampsia, even
among previously asymptomatic pregnant women (25). All
of these data suggest that autoantibodies can interfere
with early placentation, leading to increased pregnancy
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complications irrespective of the simultaneous presence or
persistence of rheumatologic symptoms. The higher first-
and second-trimester uterine artery Doppler pulsatility
indices among pregnant women with transient rheumato-
logic abnormalities in our study support these findings.
Although the association between preclinical rheu-
matic diseases and pregnancy complications seems very
plausible, our study was not population based, and there-
fore the results cannot be generalized to other popula-
tions. In addition, little is known about the prevalence of
preclinical rheumatic diseases in the general population, a
variable that could heavily influence the burden of subse-
quent complications (33). The major systemic autoim-
mune rheumatic diseases, including RA, SLE, SS, and
other CTDs, are relatively common, with a 5% prevalence
in the general population and a lifetime risk of 8.4%
among women (34). However, the natural history of these
disorders follows a pattern of progression lasting several
years from a preclinical, nondiagnostic phase to overt dis-
ease (2,3). Thus, the 2.9% prevalence of preclinical or
transient autoimmune disorders among young women
recruited into our study (150 of 5,232) was not surprising.
The biologic basis of the association between pre-
clinical autoimmune disorders and pregnancy com-
plications involves both the role of proinflammatory
cytokines and that of endothelial dysfunction associated
with inflammation (1). In particular, among subjects with
early UCTD, plasma concentrations of markers of endo-
thelial cell activation and damage are higher than those in
controls, suggesting an increased risk of atherosclerosis
(35). In addition, in these subjects there is an imbalance
between proinflammatory cytokines (interleukin-6 [IL-6],
IL-7, IL-12, IL-23) and regulatory cytokines (IL-10) that
favors vessel damage (7). Endothelial dysfunction and cyto-
kine imbalance during pregnancy can cause inadequate tro-
phoblast invasion of the spiral arteries with a subsequent
defective establishment of maternal–fetal vascularization
and oxygen and nutrient exchange, leading to FGR and
preeclampsia (1,36). An early first-trimester increase in
uterine artery Doppler pulsatility indices, a hallmark of
probable defective placentation (18) among pregnant
women with preclinical rheumatic disease, is consistent
with these data.
In conclusion, the evidence from this study sug-
gests that early, incomplete, or preclinical rheumatic
disorders diagnosed during the first trimester of pregnancy
are associated with an increased risk of preeclampsia/
FGR, SGA, or other adverse pregnancy outcomes. Even
positive autoantibody status during the first trimester with
no clinically apparent rheumatic disease at postpartum
follow-up is associated with an increased risk of fetal
growth failure. The current findings add to a growing body
of literature indicating that preclinical phases of rheumatic
disorders, although characterized by few or absent symp-
toms, could have significant adverse effects on reproduc-
tive outcomes. Since most previously published data on
this topic are based on retrospective analyses, additional
population cohort studies are needed to confirm the asso-
ciation between preclinical rheumatic diseases and adverse
obstetric outcomes and to establish the potential role of
screening measures for rheumatic disorders in the coun-
seling for, prevention of, and diagnostic evaluation of fetal
growth failure or preeclampsia.
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